BMS 433796 is a small-molecule NS5A inhibitor utilized in the research and development of antiviral drugs against hepatitis C virus (HCV). It functions by targeting the NS5A protein, which is critical for viral replication. Preclinical studies, including cell-based replicon assays, have demonstrated its potent antiviral activity and ability to suppress HCV replication. It shows promise as a potential component in future HCV therapies, with ongoing research into combinations with other antivirals to enhance efficacy and minimize resistance development.